Prediction of Chemotherapy Response by Magnetic Resonance Spectroscopy
Abstract
This research seeks to validate the use of a non-invasive tool, in vivo magnetic resonance spectroscopy (MRS), to assess therapeutic response in patients with locally-advanced breast cancer who receive primary systemic therapy (PST), also know as neoadjuvant chemotherapy. Contrast-enhanced MRI was used to measure tumor size and MRS was used to monitor tumor concentrations of choline-containing compounds TCho) known to be elevated in cancers and in cell proliferation. To date, 13 women have been followed with MRS and MRI through the complete course of PST (ACx4). Clinical response assessment by MRI was based on the response evaluation criteria in solid tumors (RECIST). Changes in TCho between the baseline scan (<1 wk before starting AC) and 24 hours after the 1st cycle of AC showed a significant positive correlation with change in tumor size measured after 4 cycles of AC (R=O.89, p<O.OOOl). Opposite trends in TCho between objective responders and nonresponders (p=O.OlOl) were observed already at 24 hours after starting PST. These results show that MRS can distinguish responders versus nonresponders early in the course of PST. These findings provide evidence that MRS can be used clinically to individualize treatments for maximizing benefit and to rapidly assess efficacy of new drugs.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2003
- Accession Number
- ADA421762
Entities
People
- Michael Garwood
Organizations
- University of Minnesota